Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients
Background: The biomarkers of immune checkpoint inhibitors (ICIs) efficacy and safety are still urgently needed. As cytokines are easily detected and monitored in circulation, they could be used as potential predictors of response and immune-related adverse events (irAEs) for ICIs therapy. Methods:...
Auteurs principaux: | Katarina Mirjačić Martinović, Ana Vuletić, Nevena Tišma Miletić, Irina Besu Žižak, Jelena Milovanović, Suzana Matković, Vladimir Jurišić |
---|---|
Format: | Article |
Langue: | English |
Publié: |
Elsevier
2023-12-01
|
Collection: | Translational Oncology |
Sujets: | |
Accès en ligne: | http://www.sciencedirect.com/science/article/pii/S1936523323001857 |
Documents similaires
-
Complete response in a patient with BRAF-mutant metastatic melanoma achieved with the multidisciplinary approach: a case report
par: Hana Garaj, et autres
Publié: (2024-01-01) -
Factors influencing the prognosis in Braf wild-type metastatic malignant melanoma and the role of novel inflammation indices
par: Senar Ebinç, et autres
Publié: (2023-09-01) -
A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
par: Wu L, et autres
Publié: (2021-02-01) -
Increased circulating monocyte MDSCs positively correlate with serum Interleukin-10 in metastatic melanoma patients
par: Katarina Mirjačić Martinović, et autres
Publié: (2023-04-01) -
Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives
par: Dugan MM, et autres
Publié: (2024-07-01)